HIGHLIGHTS
- who: Babette J. A. Verkouteren from the higher probability of achieving a complete response in the NetherlandsMaastricht University have published the Article: Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study, in the Journal: (JOURNAL) of 17/06/2020
- what: The main reasons for treatment discontinuation were toxicity (n=22) and tumour progression (n=15). This study provides important information on vismodegib effectiveness and the course of treatment after vismodegib discontinuation.
- how: To determine what tumour types achieved a complete response . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.